These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 10980631

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M, Schulz R, Cremer F, Sucker C, Schmohl D, Döhner H, Goldschmidt H, Haas R, Hunstein W.
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [Abstract] [Full Text] [Related]

  • 4. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
    Fenk R, Ak M, Kobbe G, Steidl U, Arnold C, Korthals M, Hünerlitürkoglu A, Rohr UP, Kliszewski S, Bernhardt A, Haas R, Kronenwett R.
    Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
    [Abstract] [Full Text] [Related]

  • 5. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation.
    Lipinski E, Cremer FW, Ho AD, Goldschmidt H, Moos M.
    Bone Marrow Transplant; 2001 Nov; 28(10):957-62. PubMed ID: 11753551
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T, Jedlicková K, Kriegová E, Jarosová M, Raida L, Faber E, Hubácek J, Vondráková J, Pikalová Z, Indrák K.
    Neoplasma; 2001 Nov; 48(6):501-5. PubMed ID: 11949845
    [Abstract] [Full Text] [Related]

  • 8. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation.
    Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW.
    Bone Marrow Transplant; 2000 Jan; 25(1):91-6. PubMed ID: 10654021
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma.
    Björkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G.
    Bone Marrow Transplant; 1995 Mar; 15(3):367-71. PubMed ID: 7599560
    [Abstract] [Full Text] [Related]

  • 12. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, Pedersen LM, Lauritzsen GF, Ekanger R, Nilsson-Ehle H, Nordström M, Fredén S, Jerkeman M, Eriksson M, Väärt J, Malmer B, Geisler CH.
    J Clin Oncol; 2009 Sep 10; 27(26):4365-70. PubMed ID: 19652064
    [Abstract] [Full Text] [Related]

  • 13. Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring.
    Meloni G, Proia A, Mauro F, Amaranto P, Capria S, Cimino G, Cordone I, de Fabritiis P, Rapanotti C, Reato G, Vignetti M, Foa R, Mandelli F.
    Haematologica; 2000 Sep 10; 85(9):952-60. PubMed ID: 10980634
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
    Takamatsu H, Ogawa Y, Kobayashi N, Obata K, Narisawa T, Nakayama K, Munemoto S, Aoki G, Ohata K, Kumano Y, Ozaki J, Murata R, Kondo Y, Terasaki Y, Kurokawa T, Miyamoto T, Shimizu N, Fukushima T, Yoshida A, Ueda T, Yoshida T, Nakao S.
    Exp Hematol; 2013 Oct 10; 41(10):894-902. PubMed ID: 23727584
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
    Martínez-Sánchez P, Montejano L, Sarasquete ME, García-Sanz R, Fernández-Redondo E, Ayala R, Montalbán MA, Martínez R, García Laraña J, Alegre A, Hernández B, Lahuerta JJ, Martínez-López J.
    Br J Haematol; 2008 Sep 10; 142(5):766-74. PubMed ID: 18637804
    [Abstract] [Full Text] [Related]

  • 18. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH, Runkel K, Steckel N, Opalka B, Trenschel R, Seeber S, Schaefer UW, Beelen DW.
    Bone Marrow Transplant; 2001 Apr 10; 27(8):809-15. PubMed ID: 11477437
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A, Granda A, Martínez-Chamorro C, Díaz-Mediavilla J, Martínez R, García-Laraña J, Lahuerta JJ, Sureda A, Bladé J, de la Rubia J, Fernández-Rañada JM, San Miguel J, Spanish Registry of Transplants in Multiple Myelomas, Spanish Group of Hemopoietic Transplant (GETH), PETHEMA.
    Haematologica; 2002 Jun 10; 87(6):609-14. PubMed ID: 12031917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.